ClinicalTrials.gg
RecruitingNCT07289880Updated Oct 21, 2026

Efficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes

An interventional study of Diacylglycerol oil and Colza Oil in Prediabetes, sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University. Recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.

Planned enrollment
39th of 44
40 · median 160
Started
2025
with 9 others
No phase
29 of 51
13 open now
Primary completion
2026-12
later than 8 of 24 live
Registered
41st of 51
by date

Among the 51 studies in Prediabetic State with a site in China, this one is the 39th largest by planned enrollment of the 44 interventional ones that give a count, is one of 10 that started in 2025, is one of 29 with no phase, reaches primary completion later than 8 of the 24 other live ones, and was the 41st registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prediabetic State with a site in China, or all of them as a file.
02

Study summary

This study will implement a four-week dietary intervention among middle-aged and older adults with pre-diabetes. Participants assigned to the intervention arm will replace their usual cooking oil with diacylglycerol (DAG) oil, while those in the control arm will consume colza oil. All other lifestyle behaviors will be maintained without modification. The trial will determine the impact of DAG oil consumption on glycemic regulation, lipid metabolism, and body composition in this high-risk population.

03

Conditions studied

  • Prediabetes

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 40-75 years.
  2. Diagnosed with prediabetes according to American Diabetes Association (ADA) criteria: including fasting plasma glucose (FPG) levels of 5.6-6.9 mmol/L, and/or 2-hour postprandial glucose (OGTT-2h) levels of 7.8-11.1 mmol/L, and/or (HbA1c) levels of 5.7%-6.4%.
  3. (BMI) ≥ 24 kg/m².
  4. No plans to relocate or travel extensively in the next three months.
  5. Willing to consume all study-provided meals throughout the intervention.
  6. Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of diabetes (Type 1 or Type 2).
  2. Current use of any glucose-lowering medication.
  3. Use of appetite suppressants or hormonal medications.
  4. History of bariatric surgery, or weight change >5% in the past 3 months.
  5. Alcohol consumption >40 g/day.
  6. Use of antibiotics, probiotics, or prebiotics within the past 3 months.
  7. Pregnancy, lactation or planning pregnancy.
  8. History of severe cardiovascular disease, , disease, cognitive impairment, or severe dysfunction of thyroid, liver, kidney, or digestive system.
  9. Inability to comprehend information, communicate effectively, or comply with the study protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    DAG Oil Group

    A four-week dietary intervention will be implemented, during which participants assigned to the intervention group will replace their habitual cooking oil with diacylglycerol (DAG) oil.

    Combination Product: Diacylglycerol oil

  • Active comparator
    Control Group

    Participants assigned to the control group will consume colza oil as their cooking oil throughout a four-week dietary intervention. No other lifestyle habits or dietary behaviors will be altered.

    Combination Product: Colza Oil

Interventions

  • Combination productDiacylglycerol oil

    This study will implement a four-week dietary intervention in which participants assigned to the intervention group will replace their habitual cooking oil with diacylglycerol (DAG) oil. All other lifestyle behaviors will be maintained without modification.

  • Combination productColza Oil

    Participants assigned to the control group will consume colza oil as their cooking oil throughout a four-week dietary intervention. No other lifestyle habits or dietary behaviors will be altered.

06

What researchers measure

Primary outcomes

  1. Continuous Glucose Monitoring (CGM) Data

    At baseline, and 4 weeks, investigators will using Continuous Glucose Monitoring (CGM) to monitor the glucose level of participants.

    Time frame: up to 4 weeks

Secondary outcomes

  1. weight

    At baseline, and 4 weeks, investigators will examine weight.

    Time frame: up to 4 weeks

  2. fasting blood glucose

    At baseline, and 4 weeks, investigators will use automatic electrochemiluminescence analyzer to examine fasting blood glucose.

    Time frame: At baseline and after 4 weeks of intervention

  3. lipid metabolism

    At baseline, and 4 weeks, investigators will use automatic electrochemiluminescence analyzer to examine total cholesterol, low density lipoprotein, high density lipoprotein, triglyceride.

    Time frame: At baseline and after 4 weeks of intervention

  4. HbA1c

    At baseline, and 4 weeks, investigators will use automatic electrochemiluminescence analyzer to examine HbA1c.

    Time frame: At baseline and after 4 weeks of intervention

  5. intestinal bacteria

    At baseline, and 4 weeks, investigators will use 16S rRNA pyrosequencing to examine intestinal bacteria.

    Time frame: up to 4 weeks

  6. TIR (time in range)

    TIR refers to the time when blood glucose is controlled within a reasonable ( target ) range (3.9\~10.0 mmol/L), measured by continuous glucose monitoring at baseline and 4 weeks.

    Time frame: At baseline and after 4 weeks of intervention

  7. sleep quality

    Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), which comprises seven components (A through G), each scored on a scale of 0-3. The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: up to 4 weeks

  8. blood pressure

    At baseline, and 4 weeks, investigators will test the systolic blood pressure and diastolic blood pressure using automatic digital blood pressure monitor.

    Time frame: up to 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Beijing Street
    Guangzhou, Guangdong 510000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 11 months is below that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartActual
Dec 30, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 30, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
Beijing Street is now Recruiting
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    Beijing Street is now Recruiting
    + 3 other changes: identifiers, date precision and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07289880
Lead sponsor
The First Affiliated Hospital of Guangdong Pharmaceutical University
Responsible party
Qiu-ye Lan (Associate Researcher, Guangdong Pharmaceutical University) — Principal investigator
First posted
Dec 17, 2025
Start date
Dec 30, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

QiuYe Dr. Lan
Contact
lanqiuye@gdpu.edu.cn
+86-18520395821

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacylglycerol oil

Start the discussion